Browsing Tag
lutetium-177
4 posts
Radiopharm Theranostics begins third-cohort enrolment in Phase 1 177Lu-RAD204 trial targeting PD-L1 tumours
Find out how Radiopharm Theranostics is advancing 177Lu-RAD204 in PD-L1-positive tumours as it begins third-cohort enrolment in its Phase 1 trial.
Radiopharm Theranostics (ASX: RAD) begins third cohort in PD-L1 trial—could 177Lu-RAD204 be a game-changer?
Radiopharm Theranostics moves to third cohort in PD-L1 trial with 90mCi dose approval. Explore what this means for its radiopharmaceutical ambitions.
Radioisotopes manufacturer SHINE Medical Technologies creates pharma unit
US radioisotopes manufacturer SHINE Medical Technologies has formed a new business division called SHINE Therapeutics in a move…
SHINE raises capital for medical isotope production facility from Oaktree
SHINE Medical Technologies has secured $50 million financing with funds managed by Oaktree Capital Management to support its…